Home Subscription Services
 
   

 
The International Journal of Prosthodontics
IJP Home Page
About the Editor
Editorial Board
Accepted Manuscripts
Submit
Author Guidelines
Submission Form
Reprints / Articles
Permissions
Advertising
MEDLINE Search
 
 
 
 
 
FacebookTwitterYouTube
Quintessence Publishing: Journals: IJP
The International Journal of Prosthodontics

Edited by George A. Zarb, BChD, DDS, MS, MS, FRCD(C)

ISSN 0893-2174

Publication:
September/October 2006
Volume 19 , Issue 5

Back
Share Abstract:

Comparison of Various Treatments for Sleep Bruxism Using Determinants of Number Needed to Treat and Effect Size

Nelly T. Huynh, BS / Pierre H. Rompré, MS / Jacques Y. Montplaisir, MD, PhD, CRCP / Christiane Manzini, Cert Res / Kazuo Okura, DDS, PhD / Gilles J. Lavigne, DMD, PhD, FRCD

Pages: 435–441
PMID: 17323720

Purpose: Sleep bruxism (SB) is associated with temporomandibular pain, headaches, tooth wear, and disruption of the bed partner’s sleep. The aim of this report was to compare SB treatments from various experimental studies to guide the selection of a treatment for a large sample size study. Materials and Methods: After a literature search, randomized controlled studies of 7 pharmacologic treatments and 3 oral devices were included. The number needed to treat (NNT) was calculated from raw data from the sleep laboratory at the Hôpital du Sacré-Coeur, Montréal or from published articles when sufficient data were available. The effect size (ES) was calculated for all included studies. In the most effective treatments, the NNT ranged from 1 to 4, while a high ES was above 0.8. Results: The treatments with the best NNT and ES results were the mandibular advancement device (MAD) and clonidine. The NNT (± 95% CI) and ES were 2.2 (1.4 to 5.3) and 1.5 for the MAD, and 3.2 (1.7 to 37.3) and 0.9 for clonidine, respectively. An NNT of 3.8 (1.9 to –69.4) and an ES of 0.6 were observed with the occlusal splint, with a reduction of 42% in the SB index. NNT could not be calculated for clonazepam, although the ES was 0.9. Conclusion: Although the NNT and ES results seem to indicate that the MAD and clonidine are the most promising experimental treatments, both treatments were associated with side effects (ie, discomfort for the MAD; REM suppression and morning hypotension for clonidine). The occlusal splint and clonazepam seem to be acceptable short-term alternatives, although further longitudinal, large sample size randomized controlled trials in SB management are needed. Int J Prosthodont 2006;19:435–441

Full Text PDF File | Order Article

 

 
Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.
  © 2014 Quintessence Publishing Co Inc
 

Home | Subscription Services | Books | Journals | Multimedia | Events | Blog
Terms of Use | Privacy Policy | About Us | Contact Us | Advertising | Help | Sitemap | Catalog